Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Current Assets (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 5 years of Current Assets data on record, last reported at $411.2 million in Q4 2025.

  • For Q4 2025, Current Assets rose 22.46% year-over-year to $411.2 million; the TTM value through Dec 2025 reached $411.2 million, up 22.46%, while the annual FY2025 figure was $411.2 million, 22.46% up from the prior year.
  • Current Assets reached $411.2 million in Q4 2025 per ARQT's latest filing, up from $349.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $496.7 million in Q3 2022 and bottomed at $308.9 million in Q2 2023.
  • Average Current Assets over 5 years is $384.4 million, with a median of $374.7 million recorded in 2021.
  • Peak YoY movement for Current Assets: surged 40.7% in 2024, then tumbled 30.85% in 2025.
  • A 5-year view of Current Assets shows it stood at $402.8 million in 2021, then rose by 8.6% to $437.4 million in 2022, then dropped by 24.46% to $330.4 million in 2023, then increased by 1.63% to $335.8 million in 2024, then rose by 22.46% to $411.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $411.2 million in Q4 2025, $349.2 million in Q3 2025, and $332.8 million in Q2 2025.